ArticleJournal of translational medicine2025
CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond.Journal of immunotherapy and precision oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a highly malignant brain tumor with poor outcome, despite current therapies. CIITA-modified tumor cells, capable of presenting antigens via MHC-II, show promise in eliciting effective antitumor immune responses. The efficacy of the CIITA-based vaccination strategy has been previously demonstrated using the GL261 murine GBM model. This study aimed at verifying whether a different GBM model, the CT-2A cells, more closely resembles human GBM, could follow the same rule and importantly share cross immunity with GL261.
methodsTo assess tumor growth and immune response, immunocompetent mice were injected intracranially with either CT-2A or CIITA-modified CT-2A (CT-2A-CIITA) cells, and brain tissues were examined histologically. Additionally, mice vaccinated with GL261-CIITA cells were subsequently challenged with parental CT-2A cells in the opposite hemisphere, followed by immunohistochemical analysis of brain tissues.
resultsResults indicated that CT-2A-CIITA cells were either rejected or exhibited delayed tumor growth in immunocompetent mice. Furthermore, mice previously vaccinated with GL261-CIITA cells demonstrated efficient rejection of CT-2A tumors, suggesting the induction of cross-protective immunity. This immune response was associated with a shift from an immunosuppressive to an immunogenic tumor microenvironment, implying the development of adaptive immunity against shared tumor antigens.
conclusionsIn conclusion, these findings support the broader applicability of CIITA-based vaccination against GBM and provide the first evidence of shared immunogenic antigens between two distinct murine GBM models. This discovery opens avenues for identifying common tumor antigens through immunopeptidomics, which could inform future immunotherapeutic strategies for glioblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.